Seroatlas · Human Serome Atlas

MAPDA

N6-Methyl-AMP deaminase

Also known as: ADAL, ADAL_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q6DHV7
Gene: MAPDA
Ensembl: ENSG00000168803
Chromosome: 15
Canonical length: 355 aa
Protein class: Predicted intracellular proteins
Subcellular location: Nucleoplasm,Nuclear speckles,Vesicles

OverviewNCBI Gene

Predicted to enable adenosine deaminase activity. Predicted to be involved in adenosine catabolic process and inosine biosynthetic process. Predicted to act upstream of or within response to alcohol. Predicted to be located in cytosol. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

355 residues, UniProt reviewed canonical sequence.

>Q6DHV7|MAPDA
     1  MIEAEEQQPC KTDFYSELPK VELHAHLNGS ISSHTMKKLI AQKPDLKIHD QMTVIDKGKK
    61  RTLEECFQMF QTIHQLTSSP EDILMVTKDV IKEFADDGVK YLELRSTPRR ENATGMTKKT
   121  YVESILEGIK QSKQENLDID VRYLIAVDRR GGPLVAKETV KLAEEFFLST EGTVLGLDLS
   181  GDPTVGQAKD FLEPLLEAKK AGLKLALHLS EIPNQKKETQ ILLDLLPDRI GHGTFLNSGE
   241  GGSLDLVDFV RQHRIPLELC LTSNVKSQTV PSYDQHHFGF WYSIAHPSVI CTDDKGVFAT
   301  HLSQEYQLAA ETFNLTQSQV WDLSYESINY IFASDSTRSE LRKKWNHLKP RVLHI

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against MAPDA can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.23
Highest tissue expression: 22 nTPM

Expression across tissuesHPA

Tissue

tongue: 22 nTPM
heart muscle: 20 nTPM
retina: 20 nTPM
skeletal muscle: 19 nTPM
choroid plexus: 13 nTPM
kidney: 11 nTPM

Single-cell type

early primary spermatocytes: 153 nCPM
undifferentiated spermatogonia: 79 nCPM
myonuclei: 70 nCPM
cone photoreceptor cells: 66 nCPM
choroid plexus epithelial cells: 65 nCPM
rod photoreceptor cells: 61 nCPM

Immune cell

basophil: 5.9 nTPM
T-reg: 4.5 nTPM
eosinophil: 3.8 nTPM
naive CD8 T-cell: 2.9 nTPM
plasmacytoid DC: 2.9 nTPM
gdT-cell: 2.4 nTPM

Brain region

choroid plexus: 20 nTPM
cerebral cortex: 16 nTPM
hypothalamus: 14 nTPM
cerebellum: 14 nTPM
thalamus: 14 nTPM
midbrain: 14 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.17
gnomAD pLI: 0
DepMap mean gene effect: -0.09
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

adenosine deaminase activity
metal ion binding
N6-methyl-AMP deaminase activity

Cellular components

cytosol

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads MAPDA as an antibody target. Whether an autoantibody or antibody against MAPDA could matter depends on whether native MAPDA is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

MAPDA is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label MAPDA as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...